Clinical trial
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
NCT00240682 · Centre Hospitalier of Chartres, Other · Completed
Key facts
| NCT number | NCT00240682 |
|---|---|
| Title | Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR |
| Official title | Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR. |
| Acronym | CTXSCC |
| Lead sponsor | Centre Hospitalier of Chartres, Other |
| Collaborators | Hospital of Chartres- France |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Skin Diseases, Carcinoma, Squamous Cell |
| Intervention type | Drug |
| Interventions | cetuximab |
| Enrollment | 37 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Oct 18, 2005 |
| Last update posted | Feb 22, 2012 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: